Clinical trials material must be produced with: Response:

Question

Options

• ANo consideration for packaging
• BThe same GMP standards as commercial products
• CRandom labeling practices
• DLimited documentation

• A
  6% (2)
• B
  82% (27)
• C
  3% (1)
• D
  9% (3)

Explanation

Clinical trial materials must be produced under the same Good Manufacturing Practice (GMP) standards as commercial products because patient safety is the primary concern regardless of whether a product is in development or on the market - errors in manufacturing can directly harm trial participants and invalidate study results.

Why the distractors are wrong:

• A (No consideration for packaging): Incorrect - packaging in clinical trials is critical, as it must protect the product, maintain blinding (in blinded studies), and include proper labeling for traceability.
• C (Random labeling practices): Incorrect - labeling must be highly controlled and systematic; randomized labeling would compromise patient safety and regulatory compliance.
• D (Limited documentation): Incorrect - clinical trial manufacturing actually requires extensive documentation (batch records, deviation reports, certificates of analysis) to ensure reproducibility and regulatory audit readiness.

Memory tip: Think "Patients don't care if it's a trial." From a safety standpoint, a trial participant deserves the same manufacturing rigor as a paying commercial customer - GMP standards apply uniformly, no exceptions.

No community discussion yet for this question.